icosiMED

icosiMED is a venture-backed biotechnology company developing a first-in-class oral therapy aimed at transforming metabolic health and weight management. The company’s approach is designed to disrupt the body's conversion of dietary carbohydrates into stored fat, effectively mimicking the physiological benefits of fasting without the need for appetite suppression or caloric deprivation. Unlike current GLP-1 receptor agonist therapies, which are often associated with gastrointestinal side effects and the loss of lean muscle mass, icosiMED’s lead candidate, ico101, is engineered to prevent fat accumulation while simultaneously preserving or increasing lean muscle mass, strength, and endurance. The company’s scientific foundation is supported by decades of research and human genetic validation, demonstrating that individuals who naturally lack the targeted gene exhibit an extremely lean phenotype.

This technology addresses a major challenge in the weight management market, where high patient discontinuation rates and subsequent rebound weight gain remain significant obstacles to long-term success. By offering a solution that allows for sustainable weight control without forcing patients to restrict food intake, icosiMED aims to improve quality of life and promote healthy aging. Preclinical models have shown that the company's mechanism also contributes to increased energy levels and longevity. Based in Fayetteville, Arkansas, and supported by VIC Tech, the company is focused on advancing its lead candidate toward clinical trials and pursuing strategic partnerships to address metabolic conditions such as MASLD/MASH in addition to general weight management.